Metastatic breast cancer trials in Japan

In Japan 23 Also abroad 610

23 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Kashiwa
Age
18 years and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 2Taking people
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
Where
Chiba, Fukuoka, Hirakata, Hiroshima, Ina, Isehara, Kagoshima, Kōtō City, Kumamoto, Nagoya, Osaka, Sakaishi, Sapporo, Shimotsuke, Shizuoka, Suita, Tokyo, Tsu, Tsukuba, Yokohama
Age
18 years and over
People
70
Run by
Stemline Therapeutics, Inc.
See details and how to joinNCT07766018
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Aichi, Chiba, Fukushima, Hiroshima, Hokkaido, Kanagawa, Okayama, Saitama, Tokyo
Age
18 years and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
Phase 3Taking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima, Kahoku-gun, Kōtoku, Kyoto, Nagoya, Okinawa, Otashi, Saitama, Sapporo, Sendai, Shinagawa City, Shizuoka, Suita, Tsukuba, Yokohama
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
Phase 3Taking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
Akita, Chiba, Chūō, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima, Matsuyama, Minato, Nagoya, Okayama, Osaka, Sakai, Sapporo, Shinagawa, Sunto-gun, Tsu
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
Phase 1Taking people
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Where
Hirakata
Age
18 years and over
People
194 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07604571
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto, Kyoto, Matsuyama, Nagoya, Osaka, Ota-shi, Sapporo, Sendai, Shinagawa-ku, Suita-shi, Sunto-gun, Takasaki-shi, Tsu, Yokohama
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Where
Nagoya
Age
18 years and over
People
181 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06686394
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Bunkyo-ku, Chiba, Chuo-ku, Chuo Ku, Fukuoka, Hiroshima, Isehara, Kashiwa, Koto, Matsuyama, Okayama, Otashi, Shinjuku-ku, Suita, Tokyo, Yokohama
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama, Tokyo
Age
18 years and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
Phase 1Taking people
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Where
Kashiwa, Nagoya, Suntogun
Age
18 years and over
People
433 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Bunkyo, Fukushima, Gifu, Hidaka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kawasaki, Koto, Kumamoto, Kyoto, Nagoya, Okayama, Osaka, Sagamihara, Sapporo, Sendai, Shinagawa, Shinjuku, Suita, Tsu, Yokohama
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 1Taking people
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
Where
Kyoto
Age
18 years and over
People
66 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07801508
Phase 3Taking people
Metastasis-directed Therapy for Oligometastases of Breast Cancer
Where
Bunkyō-Ku
Age
18 years and over
People
146
Run by
Tokyo Medical and Dental University
See details and how to joinNCT06135714
Phase 1Taking people
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Where
Chuo Ku, Hirakata, Kashiwa, Koto-ku
Age
18 years and over
People
234 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06997029 · EU 2025-524334-26-01
Phase 1/2Taking people
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Where
Chuo Ku, Fukuoka, Fukushima, Hirakata, Isehara, Kashiwa, Koto-Ku, Osaka, Shinagawa-Ku, Yokohama
Age
18 years and over
People
220 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00
No phaseTaking people
EORTC Metastatic Breast Cancer Module Development
Where
Osaka, Tokyo
Age
18 years and over
People
568 worldwide
Run by
University of Leeds
See details and how to joinNCT07806266
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Chuo Ku
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
Phase 1/2Taking people
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Where
Fukuoka, Hirakata, Kōtō City, Kyoto
Age
18 years and over
People
880 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00
Phase 1/2Taking people
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Where
Nagoya
Age
18 years and over
People
86
Run by
Nagoya City University
See details and how to joinNCT07164976
Phase 2Taking people
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
Where
Koto-ku, 3-8-31
Age
18 years and over
People
106
Run by
Japan Breast Cancer Research Group
See details and how to joinNCT06793553